title: Liver transplantation for homozygous familial hypercholesterolemia: two case reports.
abstract: Homozygous familial hypercholesterolemia (HFHC) is a rare inherited condition with an incidence of one in one million. It is associated with severe premature atherosclerosis and early death from cardiovascular complications. Mutation in the gene that encodes the synthesis of the cellular receptor for low-density lipoprotein (LDL) is responsible for this metabolic disorder. Currently, the only effective treatment for this disease is liver transplantation, which alone or in association with medications, normalizes plasma cholesterol level. The authors report the results of liver transplantation for two cases of HFHC. The first case, a 15-year-old boy received a whole liver from a deceased donor, and the second, an 11-year-old boy, received a left liver lobe transplant from his mother's sister. Their preoperative fasting lipid concentrations were grossly raised. The older boy had severe atherosclerotic heart disease and had undergone coronary artery bypass grafting 5 months before transplantation. Both had preoperative plasma cholesterol levels higher than 750 mg/dL with normal thyroid and liver function tests. After the operation, the patients received methylprednisolone as pulse therapy followed by oral prednisolone, mycophenolate mofetil, and tacrolimus for immunosuppression. Their hospital stays were 24 and 13 days, respectively. The first case needed reexploration because of bleeding on the second day after the operation. The lipid concentrations rapidly returned to the normal range in the first week after the operation, remaining in this range over the first 6 months of follow-up. Liver transplantation offers an highly effective treatment for HFHC. It is better to operate on patients before severe atherosclerotic changes in the coronary arteries. All patients must undergo a complete cardiac evaluation before surgery.
authors.affiliation: Shiraz Transplant Center, Namazi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.
authors.forename: F
authors.initials: F
authors.lastname: Kakaei
authors.forename: S
authors.initials: S
authors.lastname: Nikeghbalian
authors.forename: K
authors.initials: K
authors.lastname: Kazemi
authors.forename: H
authors.initials: H
authors.lastname: Salahi
authors.forename: A
authors.initials: A
authors.lastname: Bahador
authors.forename: S M
authors.initials: SM
authors.lastname: Dehghani
authors.forename: M
authors.initials: M
authors.lastname: Dehghani
authors.forename: S M
authors.initials: SM
authors.lastname: Nejatollahi
authors.forename: A
authors.initials: A
authors.lastname: Shamsaeefar
authors.forename: M B
authors.initials: MB
authors.lastname: Khosravi
authors.forename: S A
authors.initials: SA
authors.lastname: Malek-Hosseini
mesh_terms: D000293:Adolescent; D002648:Child; D002784:Cholesterol / Q000097:blood; D004359:Drug Therapy, Combination; D006720:Homozygote; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000235:genetics / Q000601:surgery*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008055:Lipids / Q000097:blood; D016031:Liver Transplantation / Q000276:immunology; D008297:Male; D012016:Reference Values; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D008055:Lipids; D002784:Cholesterol